Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity.
+ 3 more risks
Adequate balance sheet with limited growth.
Share Price & News
How has Obalon Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OBLN's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: OBLN underperformed the US Medical Equipment industry which returned -7.7% over the past year.
Return vs Market: OBLN underperformed the US Market which returned -15.9% over the past year.
Price Volatility Vs. Market
How volatile is Obalon Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall StThe Obalon Therapeutics (NASDAQ:OBLN) Share Price Is Down 98% So Some Shareholders Are Very Salty
3 months ago | Simply Wall StHere's Why Obalon Therapeutics (NASDAQ:OBLN) Must Use Its Cash Wisely
3 months ago | Simply Wall StCould Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?
Is Obalon Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OBLN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OBLN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: OBLN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OBLN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OBLN is good value based on its PB Ratio (0.3x) compared to the US Medical Equipment industry average (2.9x).
How is Obalon Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if OBLN's forecast earnings growth is above the savings rate (1.7%).
Earnings vs Market: Insufficient data to determine if OBLN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: OBLN's revenue (72.2% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: OBLN's revenue (72.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OBLN's Return on Equity is forecast to be high in 3 years time
How has Obalon Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OBLN is currently unprofitable.
Growing Profit Margin: OBLN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OBLN is unprofitable, and losses have increased over the past 5 years at a rate of -18% per year.
Accelerating Growth: Unable to compare OBLN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBLN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: OBLN has a negative Return on Equity (-149.38%), as it is currently unprofitable.
How is Obalon Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: OBLN's short term assets ($18.2M) exceed its short term liabilities ($4.0M).
Long Term Liabilities: OBLN's short term assets ($18.2M) exceed its long term liabilities ($567.0K).
Debt to Equity History and Analysis
Debt Level: OBLN is debt free.
Reducing Debt: OBLN has no debt compared to 5 years ago when its debt to equity ratio was 32.8%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OBLN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OBLN has less than a year of cash runway if free cash flow continues to reduce at historical rates of -16.2% each year
What is Obalon Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OBLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate OBLN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OBLN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OBLN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OBLN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
William Plovanic (50yo)
Mr. William John Plovanic, also known as Bill, CFA serves as Chief Executive Officer at Obalon Therapeutics, Inc. since October 19, 2019. Mr. Plovanic serves as President and Director of Obalon Therapeutic ...
CEO Compensation Analysis
Compensation vs Market: William's total compensation ($USD955.62K) is above average for companies of similar size in the US market ($USD626.39K).
Compensation vs Earnings: William's compensation has been consistent with company performance over the past year.
|Executive Chairman of the Board||1.25yrs||US$526.00k||0.90% $44.9k|
|Chief Technology Officer||3.42yrs||US$542.67k||0.50% $25.2k|
|Chief Quality Assurance||1.25yrs||US$539.52k||0.15% $7.6k|
|Chief Financial Officer||0.50yr||no data||0.21% $10.6k|
|Chief Retail Officer||0.92yr||no data||0.068% $3.4k|
Experienced Management: OBLN's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.
|Executive Chairman of the Board||1.25yrs||US$526.00k||0.90% $44.9k|
|Independent Director||12.25yrs||US$117.50k||0.13% $6.7k|
|Independent Director||4.08yrs||US$130.00k||0.036% $1.8k|
|Independent Director||4.25yrs||US$132.50k||0.15% $7.5k|
|Independent Director||12.25yrs||US$130.00k||0.25% $12.6k|
|Independent Director||7.92yrs||US$115.00k||no data|
|Independent Director||3.08yrs||US$122.50k||0.0071% $356.7|
Experienced Board: OBLN's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 147.2%.
Obalon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Obalon Therapeutics, Inc.
- Ticker: OBLN
- Exchange: NasdaqGM
- Founded: 2008
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$5.003m
- Shares outstanding: 7.70m
- Website: https://www.obalon.com
Number of Employees
- Obalon Therapeutics, Inc.
- 5421 Avenida Encinas
- Suite F
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|OBLN||NasdaqGM (Nasdaq Global Market)||Yes||Common Shares||US||USD||Oct 2016|
|24OA||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Oct 2016|
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/06 04:44|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.